Study links Alport genetics to kidney symptoms
Part of Genetic & congenital, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study looks at how specific genetic changes (genotypes) relate to kidney problems and urine blood findings in people with Alport syndrome. It may help doctors predict disease course and tailor care, though it may not involve new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be any age (including children and older adults, up to age 99)
- Have a history of blood in the urine from kidney problems (renal hematuria)
- Have had Alport syndrome in your family or in your own history
- Be able to sign the study consent form
- Have enough past medical records and kidney test results to complete the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether an ACE inhibitor (a blood-pressure/kidney-protecting medicine) is safe and effective for adults with Alport syndrome caused by certain COL4A3/COL4A4/COL4A5 gene variants. It aims to see if treatment can help protect kidney function in people who currently have signs like blood or small amounts of protein in the urine.
This study follows people diagnosed with Alport syndrome to better understand the condition and its effects. It may help researchers learn what to watch for over time and how the disease progresses.
This is a registry that collects information from people with Alport syndrome to better understand the disease and how to delay kidney failure. It may help researchers learn which factors and treatments are most important over time.
This registry collects health information from people with Alport syndrome to help researchers better understand the condition and improve future treatments.
This study tests a new medicine called BAY 3401016 to see if it can help adults with Alport syndrome, a genetic condition that affects the kidneys. The drug is given as an infusion or injection and the study will check how well it works and if it is safe.
This trial tests whether umbilical cord stem cells can help children with Alport syndrome who have kidney damage. The goal is to see if the treatment can slow down kidney disease and improve symptoms.
Hear when a new Alport Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.